Copyright
©The Author(s) 2022.
World J Gastrointest Oncol. Jan 15, 2022; 14(1): 253-264
Published online Jan 15, 2022. doi: 10.4251/wjgo.v14.i1.253
Published online Jan 15, 2022. doi: 10.4251/wjgo.v14.i1.253
Table 2 Hepatocellular carcinoma patients based on Lnc524369 levels
| Higher expression (n = 22) | Lower expression (n = 19) | t/χ2 | P | ||
| Age | 57.68 ± 10.77 | 54.21 ± 11.44 | 1.000 | 0.688 | |
| Male | 13 (59.1%) | 12 (63.16%) | 0.004 | 0.952 | |
| Pathological grading | Low | 9 (40.91%) | 2 (10.53%) | ||
| Moderate | 11 (50.00%) | 10 (52.63%) | - | 0.009 | |
| High | 2 (9.09%) | 7 (36.84%) | |||
- Citation: Zheng W, Shen GL, Xu KY, Yin QQ, Hui TC, Zhou ZW, Xu CA, Wang SH, Wu WH, Shi LF, Pan HY. Lnc524369 promotes hepatocellular carcinoma progression and predicts poor survival by activating YWHAZ-RAF1 signaling. World J Gastrointest Oncol 2022; 14(1): 253-264
- URL: https://www.wjgnet.com/1948-5204/full/v14/i1/253.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v14.i1.253